Explore this issueOctober 2013
Also by this Author
MADRID—The latest European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis give a somewhat greater nod to the use of combination conventional disease-modifying antirheumatic drugs (DMARDs) than past recommendations did, but leaves monotherapy with methotrexate as a perfectly acceptable first-line treatment.
The recommendations also keep all biologic DMARDs—such as tumor necrosis factor (TNF) inhibitors—as second-line treatments, according to a presentation by Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, who spoke on behalf of the 33-member task force that wrote the updated recommendations. He made his remarks in a presentation at the EULAR 2013 Annual European Congress of Rheumatology, held June 12–15.